Trial Profile
Phase 2 Study of Nivolumab in Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 31 Dec 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Myeloproliferative disorders
- Focus Therapeutic Use
- 01 Dec 2021 Results published in the Annals of Hematology
- 26 Oct 2018 Status changed to discontinued.
- 31 Oct 2017 Status changed from recruiting to active, no longer recruiting.